Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel

BACKGROUND: Current guidelines for the treatment of human epidermal growth factor receptor 2‒negative (HER2−) advanced breast cancer (ABC) are informed by tumor characteristics and include platinum- and non–platinum-based chemotherapy, chemotherapy plus immunotherapy, endocrine monotherapy, or endoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahtani, Reshma, Niyazov, Alexander, Arondekar, Bhakti, Lewis, Katie, Rider, Alex, Massey, Lucy, Lux, Michael Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650077/
https://www.ncbi.nlm.nih.gov/pubmed/36368161
http://dx.doi.org/10.1016/j.breast.2022.10.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650077/
https://www.ncbi.nlm.nih.gov/pubmed/36368161
http://dx.doi.org/10.1016/j.breast.2022.10.009

Ejemplares similares